Skip to main content
Equibles
CELU logo

CELU · Celularity Inc · Metrics

Track CELU — free

Use CELU with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CELU.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.68 -0.07 (-8.81%) At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Oct 20, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has evaluated the Company’s current financial position, liquidity, capital resources, and projected cash flows and has determined that there is substantial doubt about the Company’s ability to continue as a going concern. Accordingly, management cannot conclude that it is probable these plans will be successfully implemented or that, if implemented, they will alleviate the substantial doubt.”
View the 10-Q filed Oct 20, 2026
Market Cap
$22.22M
Shares
32.45M
Volume · Nov 12 122.11K Avg daily vol (3M) 3.87M

CELU metrics

76 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.68
Market cap
$22.22M

Price action

23 metrics
Price change (1W)
-7.1%
Price change (30D)
-47.1%
Price change (3M)
+8.8%
Price change (6M)
-4.6%
Price change (YTD)
-32.3%
Price change (1Y)
-56.3%
Trailing year
Price change (5Y)
—
52-week high
$2.10
52-week low
$0.60
Change from 52-week high
-64.2%
Change from 52-week low
+25.6%
Annualized volatility
170.3%
Annualized volatility (3M)
302.9%
Implied volatility (30D)
229.4%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
2.0
RSI (14D)
37.0
Price vs SMA 50
-38.8%
Price vs SMA 200
-29.5%
Avg volume (3M)
3.87M
Relative volume
0.0
Average dollar volume
$7.84M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
32.45M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.3×
reciprocal yield 76.6%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-188.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
5.9×
reciprocal yield 17.1%
EV / revenue historical average (5Y)
5.9×
reciprocal yield 17.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
19.2%
Operating margin
-264.3%
Trailing 12 months
Net margin
-245.7%
Gross profit (TTM)
$3.59M
Operating profit (TTM)
−$49.33M
Net income (TTM)
−$45.86M
Trailing 12 months
Diluted EPS (TTM)
$-1.69
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.66
Gross profit per diluted share (TTM)
$0.12
Operating profit per diluted share (TTM)
$-1.74
EBITDA per diluted share (TTM)
$-1.51
Net income per diluted share (TTM)
$-1.68
Operating cash flow per diluted share (TTM)
$-0.33
Free cash flow per diluted share (TTM)
$-0.31
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.46
Stock compensation per diluted share (TTM)
—
Book value per share
$-1.21

Growth

11 metrics
Revenue growth YoY
-5.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$18.67M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+22.2%
Year over year · more shares
Revenue CAGR (3Y)
+13.9%
Revenue CAGR (5Y)
+13.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-47.7%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$42.56M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$586,000
Total assets
$96.17M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.92M
Capital expenditures (TTM)
$161,000
R&D (TTM)
$12.97M
SG&A (TTM)
$38.48M
Stock compensation (TTM)
—
R&D / revenue
69.5%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
40
13F filer change QoQ
+1
Institutional ownership
6.9%
Conviction holders (share of 13F filers)
2.5%
Crowding (high-turnover and private-fund holders)
1.0%
Private-fund adviser ownership
0.5%
Active holders' share change QoQ
+36.9%
Holder tenure
6.4
Price vs estimated holder cost
-91.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.4%

Short interest

3 metrics
Short interest
1.6%
Latest settlement · 2.3 days to cover
Days to cover
2.3d
Short-squeeze score
49 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1752828 CUSIP 151190204 13F (30d) 33 filings 22 filers Visit website Investor relations